The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Why are there hotspot mutations in the TP53 gene in human cancers?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most frequent mutation locations of the DBD are known as “hotspots,” which contain codons G245, R249, R248, R282, R273, Y220, and R175144”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [144]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Self-citationBouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Critical assessment of methods of protein structure prediction (CASP) — round x
Moult, J., Fidelis, K., Kryshtafovych, A., Schwede, T., & Tramontano, A. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24452 · Cited by 652
Harvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Self-citation
Cited by
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
The p53 network: cellular and systemic DNA damage responses in cancer and aging
Vaddavalli, P. L., & Schumacher, B. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.010 · Cited by 279
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 275
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Self-citationZhan, H., Xie, H., Zhou, Q., Liu, Y., & Huang, W. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00202 · Cited by 36
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Functional investigations of p53 acetylation enabled by heterobifunctional molecules
Chen, L.-Y., Singha Roy, S. J., Jadhav, A. M., Wang, W. W., Chen, P.-H., Bishop, T., Erb, M. A., & Parker, C. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00438 · Cited by 18
Hwang, J., Likasitwatanakul, P., Deshmukh, S. K., Wu, S., Kwon, J. J., Toye, E., Moline, D., Evans, M. G., Elliott, A., Passow, R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3471 · Cited by 12
Immortalization of primary marmoset skin fibroblasts by CRISPR-Cas9-mediated gene targeting
Jeong, Y.-J., Cho, J., Kwak, J., Sung, Y. H., & Kang, B.-C. (2022) · Animal Cells and Systems · doi:10.1080/19768354.2022.2151509 · Cited by 11
PDBminer to Find and Annotate Protein Structures for Computational Analysis
Degn, K., Beltrame, L., Tiberti, M., & Papaleo, E. (2023) · doi:10.1101/2023.05.06.539447 · Cited by 6
PDBminer to Find and Annotate Protein Structures for Computational Analysis
Degn, K., Beltrame, L., Tiberti, M., & Papaleo, E. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00884 · Cited by 6
Bioinformatic Identification of TP53 Gene Mutation Hotspots in Colorectal Cancer
Kovács, Z., Sugimura, H., György, T. A., Osvath, E., Manirakiza, F., & Gurzu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126612 · Cited by 5
Jin, J., Huo, L., Fan, Y., Wang, R., Scott, A. W., Pizzi, M. P., Yao, X., Shao, S., Ma, L., Da Silva, M. S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1062424 · Cited by 3
Metadata
- Authors
- Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A., & Chan, C. S.
- Venue
- Cell Death & Differentiation
- Published
- 2017-11-03
- Volume
- 25
- Issue
- 1
- Pages
- 154-160
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2765694924
- Cited by
- 607
- References
- 22
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.